ERCC1 as a risk stratifier in platinum-based chemotherapy for nonsmall-cell lung cancer

Current Opinion in Pulmonary Medicine

Volumn 13, Issue 4, 2007, Pages 284-289

  Olaussen, Ken André ^a   Mountzios, Giannis ^a   Soria, Jean Charles ^a  

^a INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Biomarkers; Customized chemotherapy; Lung cancer; Predictive; Prognostic

Indexed keywords

ALKYLATING AGENT; BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; DOCETAXEL; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; F 11782; FLUORINE DERIVATIVE; GEMCITABINE; MESSENGER RNA; MITOMYCIN C; NAVELBINE; OXALIPLATIN; PACLITAXEL; PROTEIN INHIBITOR; UNCLASSIFIED DRUG; VINDESINE;

CANCER ADJUVANT THERAPY; CANCER CELL; CANCER COMBINATION CHEMOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL TRIAL; DISEASE MARKER; DNA ADDUCT; DNA REPAIR; GENE EXPRESSION; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; METHODOLOGY; PATIENT MONITORING; PREDICTION; PROTEIN EXPRESSION; RANDOMIZATION; REVIEW; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; CISPLATIN; DNA-BINDING PROTEINS; ENDONUCLEASES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG NEOPLASMS; PLATINUM; PROGNOSIS; RISK FACTORS; RNA, NEOPLASM; TUMOR MARKERS, BIOLOGICAL;

EID: 34249819963     PISSN: 10705287     EISSN: 15316971     Source Type: Journal    
DOI: 10.1097/MCP.0b013e32816b5c63     Document Type: Review

References (47)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55:74-108.
2. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med 2004; 350:379-392.
3. Blackhall F, Thatcher N. Chemotherapy for advanced lung cancer. Eur J Cancer 2004; 40:2345-2348.
4. Sekine I, Minna JD, Nishio K, et al. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol 2006; 1:31-37. A critical review comparing results from about 30 clinical studies of candidate markers for chemosensitivity.
5. Evans E, Moggs JG, Hwang JR, et al. Mechanism of open complex and dual incision formation by human nucleotide excision repair factors. EMBO J 1997; 16:6559-6573.
6. Mu D, Hsu DS, Sancar A. Reaction mechanism of human DNA repair excision nuclease. J Biol Chem 1996; 271:8285-8294.
7. Sancar A. Mechanisms of DNA excision repair. Science 1994; 266:1954-1956.
8. Zamble DB, Mu D, Reardon JT, et al. Repair of cisplatin-DNA adducts by the mammalian excision nuclease. Biochemistry 1996; 35:10004-10013.
9. Altaha R, Liang X, Yu JJ, Reed E. Excision repair cross complementing-group 1: gene expression and platinum resistance. Int J Mol Med 2004; 14:959-970.
10. Dabholkar M, Bostick-Bruton F, Weber C, et al. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cancer Inst 1992; 84:1512-1517.
11. Dabholkar M, Vionnet J, Bostick-Bruton F, et al. Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. J Clin Invest 1994; 94:703-708.
12. Joshi MB, Shirota Y, Danenberg KD, et al. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005; 11:2215-2221.
13. Langer R, Specht K, Becker K, et al. Association of pretherapeutic expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005; 11:7462-7469.
14. Lord RV, Brabender J, Gandara D, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in nonsmall cell lung cancer. Clin Cancer Res 2002; 8:2286-2291.
15. Metzger R, Leichman CG, Danenberg KD, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16:309-316.
16. Reed E, Dabholkar M, Thornton K, et al. Evidence for in the appearance of mRNAs of nucleotide excision repair genes, in human ovarian cancer tissues. Oncol Rep 2000; 7:1123-1128.
17. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in nonsmall-cell lung cancer. Lung Cancer 2002; 38:217-227.
18. Shirota Y, Stoehlmacher J, Brabender J, et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19:4298-4304.
19. Warnecke-Eberz U, Metzger R, Miyazono F, et al. High specificity of quantitative excision repair cross-complementing 1 messenger RNA expression for prediction of minor histopathological response to neoadjuvant radiochemotherapy in esophageal cancer. Clin Cancer Res 2004; 10:3794-3799.
20. Wei Q, Frazier ML, Levin B. DNA repair: a double-edged sword. J Natl Cancer Inst 2000; 92:440-441.
21. Furuta T, Ueda T, Aune G, et al. Transcription-coupled nucleotide excision repair as a determinant of cisplatin sensitivity of human cells. Cancer Res 2002; 62:4899-4902.
22. Hoeijmakers JH. Genome maintenance mechanisms for preventing cancer. Nature 2001; 411:366-374.
23. Volker M, Mone MJ, Karmakar P, et al. Sequential assembly of the nucleotide excision repair factors in vivo. Mol Cell 2001; 8:213-224.
24. Nunez F, Chipchase MD, Clarke AR, Melton DW. Nucleotide excision repair gene (ERCC1) deficiency causes G(2) arrest in hepatocytes and a reduction in liver binucleation: the role of p53 and p21. FASEB J 2000; 14:1073-1082.
25. Nonsmall Cell Lung Cancer Collaborative Group. Chemotherapy in nonsmall cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 1995; 311:899-909.
26. Scagliotti GV, Fossati R, Torri V, et al. Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA nonsmall-cell lung cancer. J Natl Cancer Inst 2003; 95:1453-1461.
27. The International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected nonsmall-cell lung cancer. N Engl J Med 2004; 350:351-360.
28. Winton T, Livingston R, Johnson D, et al. Vinorelbine plus cisplatin vs. observation in resected nonsmall-cell lung cancer. N Engl J Med 2005; 352:2589-2597.
29. Douillard JY, Rosell R, DeLena M, et al. Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA nonsmall-cell lung cancer (Adjuvant Navelbine International Trialist Association [ANITA]): a randomised controlled trial. Lancet Oncol 2006; 7:719-727.
30. Strauss GM, Herndon J, Maddaus A, et al. Randomized clinical trial of adjuvant chemotherapy with paclitaxel and carboplatin following resection in Stage IB nonsmall cell lung cancer: Report of Cancer and Leukemia Group B (CALGB) Protocol 9633 [abstract]. J Clin Oncol (ASCO Annual Meeting Proceedings) 2004; 22:7019.
31. Le Chevalier T, Arriagada R, Pignon JP, Scagliotti GV. Should adjuvant chemotherapy become standard treatment in all patients with resected nonsmall-cell lung cancer? Lancet Oncol 2005; 6:182-184.
32. Olaussen KA, Ariane D, Fouret P, et al. DNA repair by ERCC1 in nonsmall-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med 2006; 355:983-991. The largest study ever conducted that validates the notion of ERCC1 as a predictor for cisplatin-based chemotherapy using standard methods of immunohistochemistry.
33. Simon GR, Sharma S, Cantor A, et al. ERCC1 expression is a predictor of survival in resected patients with nonsmall cell lung cancer. Chest 2005; 127:978-983.
34. Zheng Z, Chen T, Li X, et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007; 356:800-808. This remarkable study of 187 early-stage NSCLC specimens demonstrated that patients with high tumor expression of both RRM1 and ERCC1 have excellent prognosis.
35. Isla D, Sarries C, Rosell R, et al. Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced nonsmall-cell lung cancer. Ann Oncol 2004; 15:1194-1203.
36. Zhou W, Gurubhagavatula S, Liu G, et al. Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced nonsmall cell lung cancer patients treated with platinum-based chemotherapy. Clin Cancer Res 2004; 10:4939-4943.
37. Rosell R, Cobo M, Isla D, et al. Pharmacogenomics and gemcitabine. Ann Oncol 2006; 17 (Suppl 5):v13-v16.
38. Rosell R, Taron M, Barnadas A, et al. Nucleotide excision repair pathways involved in Cisplatin resistance in nonsmall-cell lung cancer. Cancer Control 2003; 10:297-305.
39. Rosell R, Danenberg KD, Alberola V, et al. Ribonucleotide reductasemessenger RNA expression and survival in gemcitabine/cisplatin-treated advanced nonsmall cell lung cancer patients. Clin Cancer Res 2004; 10:1318-1325.
40. Bepler G, Kusmartseva I, Sharma S, et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in nonsmall-cell lung cancer. J Clin Oncol 2006; 24:4731-4737.
41. Ceppi P, Volante M, Novello S, et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced nonsmall-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17:1818-1825. Another recent demonstration that ERCC1-positive expression is detrimental for response to cisplatin-based chemotherapy.
42. Rosell R, Gandara D, Cobo M, et al. Customizing cisplatin based chemotherapy on quantitative excision repair cross-complementing 1 mRNA expression: a phase III randomized trial in nonsmall cell lung cancer. The 31st Congress of the European Society of Medical Oncology, 30 September-3 October 2006; Istanbul, Turkey. Ann Oncol 2006; 17 (suppl. 9): abstract LBA1.
43. Gazdar AF. DNA repair and survival in lung cancer - the two faces of Janus. N Engl J Med 2007; 356:771-773.
44. Zhu XD, Niedernhofer L, Kuster B, et al. ERCC1/XPF removes the 3′ overhang fromuncapped telomeres and represses formation of telomericDNA-containing double minute chromosomes. Mol Cell 2003; 12:1489-1498.
45. Yan QW, Reed E, Zhong XS, et al. MZF1 possesses a repressively regulatory function in ERCC1 expression. Biochem Pharmacol 2006; 71:761-771. A fundamental paper allowing a better understanding of how ERCC1 gene regulation occurs and how this is related to platinum exposure.
46. Barret JM, Cadou M, Hill BT. Inhibition of nucleotide excision repair and sensitisation of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. Biochem Pharmacol 2002; 63:251-258.
47. Reed E. ERCC1 measurements in clinical oncology. N Engl J Med 2006; 355:1054-1055. An excellent editorial that places ERCC1 and chemosensitivity into a clinical perspective.